| |
 Science
Christopher Adam, Ph.D.
Advisor, MediBIC Group
In 2003, Mr. Adam accepted
his position as the advisor of MediBIC for global business
development strategy. In 1994, Mr. Adam became Director,
Commercial Strategy Glaxo plc, following his career as President
of the French organization of Glaxo. In 1997, he accepted
a position as Regional Director Japan and was also a global
board member of GlaxoWellcome. |
|
Toru Horie, Ph.D.
Scientific Advisor, MediBIC Group
Dr. Horie accepted his position as Scientific Advisor
of MediBIC in August, 2002. He first joined Eisai Co., Ltd.
and gained experience as a researcher in the Pharmacology
and Drug Metabolism Laboratory and Pharmacokinetics Laboratory.
He was then promoted to Head of Drug Discovery Metabolism
Research Institute, Drug Discovery Division.
After leaving Eisai, he established D-Three Institute,
providing education and training opportunities to pharmaceutical
researchers, as well as consultation in the field of drug
discovery and pharmacokinetics studies.
|
|
Business
Management
Akitoshi Yamazaki, M.B.A.
Advisor, MediBIC Group
Mr. Yamazaki became an advisor of MediBIC in
May 2005. He is a graduate of Keio University, and has an
MBA degree from Columbia University.
His previous experiences are Sumitomo Corporation,
McKinsey & Company, Inc., Disney Store Japan, Inc.,
Managing Director, The Goodwill Group, Inc., Executive Director,
COMSN, Inc.
|
|
